Study urges caution about prostate cancer screening

August 7, 2014 by Reema Rattan, The Conversation
Despite screening offering gains in mortality from prostate cancer, men are more likely to die with the disease than from it. Credit: Oleh Slobodeniuk/Flickr, CC BY-SA

Prostate cancer screening could reduce deaths from the disease but it should not be routine, according to a study published today in the medical journal The Lancet.

Evidence from the European Randomised study of Screening for Prostate Cancer (ERSPC) shows screening reduces prostate cancer deaths by 15% after nine years and 21% after 13 years. One in 780 men who were screened avoided death from prostate cancer in the following 13 years.

The study, which looked at men between the ages of 50 and 74 from eight European countries, randomly divided participants into two groups – one that would receive the prostate specific antigen (PSA) test every four years (two years in Sweden) while the other was not screened.

After non-melanoma skin cancer, prostate cancer is the most common cancer in Australian men, and accounted for 30% of all new internal cancers in men in 2010.

"Going back 30 years, prostate cancer was mostly diagnosed when it was already too late to be successfully treated," said Bruce Armstrong, professor of public health at the University of Sydney.

"All that changed when radical prostatectomy came along. And in around the same period of time, it was realised that PSA testing might be useful for early detection."

The PSA test measures a prostate-specific antigen (an antigen is something that induces an immune response) in the blood. Although it's the only practical tool we have for detecting prostate cancer early, it is not particularly accurate.

The perils of PSA

"The problem with the PSA test is that, although it's prostate specific, it's not prostate cancer specific," said associate professor of evidence-based practice at Monash University Dragan Ilic.

"So men who have an enlarged prostate, for example, or an inflamed prostate due to some sort of bacterial infection may also have a very elevated PSA test result. That's where the limitations of the PSA test arise."

Widespread use of the PSA test saw prostate cancer rates shoot up, said Armstrong, and anyone looking at that and knowing about screening tests would say "wow, we're finding a lot of cancer here and possibly quite a lot that would never come to light were it not for the PSA test".

The PSA test is said to be only about 60% to 70% accurate, but all men who have above a certain level of prostate-specific antigen are usually sent for a trans-rectal ultrasound-guided biopsy. While necessary to diagnose prostate cancer, when it is there, biopsy carries a small risk of infection.

"The problem with the PSA test, and to some extent the biopsy, is that it can't readily distinguish between slow-growing cancers of the prostate, which the majority are, and fast-growing cancers, which are the ones that threaten life," said Ilic.

This appears to be the reason why the study authors do not recommend population-wide PSA screening. The worry of diagnosis of a cancer that was never itself going to cause harm is only the start of a series of harms.

Over diagnosis and over treatment

Study leader Professor Fritz Schröder from Erasmus University Medical Center in the Netherlands told The Lancet that while PSA screening delivered a substantial reduction in prostate cancer deaths, similar or greater to that reported in screening for breast cancer, over-diagnosis occurred in roughly 40% of cases detected by screening, resulting in a high risk of over-treatment and common side effects, such as incontinence and impotence.

Ultimately, it really starts to bite when treatment is given for a cancer that would not otherwise have caused a problem, Armstrong said.

Somewhere around 70% of men will be rendered unable to obtain an erection firm enough for sexual intercourse following radical treatment, and around 15% will have some problem with urinary continence on a long-term basis, he added.

Ilic said the commonly used line was that men were more likely to die with prostate cancer than from it.

"Consider this 20% lower chance of dying. One way to look at that is if you look at the figure of one in ten lifetime risk of being diagnosed with cancer as the baseline," he said. "A 20% reduction in 10% is not all that significant."

"I see the evidence as currently favouring a beneficial effect from PSA testing but it remains an open question whether or in what circumstances the benefits are sufficiently great to counter the harms of what is fairly substantial over-diagnosis," Armstrong said.

Explore further: Organized screening for prostate cancer does more harm than good

More information: The Lancet, … 614)60525-0/abstract

Related Stories

Organized screening for prostate cancer does more harm than good

September 30, 2013
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths. Now, researchers have shown that men experience more harm ...

Alternative PSA screening strategies could reduce harm

February 5, 2013
(HealthDay)—Compared with standard screening, alternative prostate-specific antigen (PSA) screening strategies could maintain good prostate cancer detection rates while reducing overdiagnoses and unnecessary biopsies, according ...

Vasectomy may increase risk of aggressive prostate cancer

July 9, 2014
Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health (HSPH). The researchers found ...

PSA-testing and early treatment decreases risk of prostate cancer death

March 10, 2014
Mortality in prostate cancer is lower in areas with frequent use of PSA testing compared with areas with little testing shows a study published online today in Journal of the National Cancer Institute by researchers from ...

Benefit of PSA reduced by loss of quality-adjusted life-years

August 16, 2012
(HealthDay) -- Although the European Randomized Study of Screening for Prostate Cancer (ERSPC) has reported a 29 percent reduction in prostate-cancer mortality for men who undergo prostate-specific antigen (PSA) screening, ...

Nearly half of all deaths from prostate cancer can be predicted before age 50

April 16, 2013
Focusing prostate cancer testing on men at highest risk of developing the disease is likely to improve the ratio between benefits and the harms of screening, suggests a paper published today in BMJ.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.